Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

MLA

Butler, Javed, et al. “Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.” Circulation, vol. 140, no. 25, Dec. 2019, pp. 2108–18. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.119.042155.

APA

Butler, J., Packer, M., Greene, S. J., Fiuzat, M., Anker, S. D., Anstrom, K. J., Carson, P. E., Cooper, L. B., Fonarow, G. C., Hernandez, A. F., Januzzi, J. L., Jessup, M., Kalyani, R. R., Kaul, S., Kosiborod, M., Lindenfeld, J., McGuire, D. K., Sabatine, M. S., Solomon, S. D., & Teerlink, J. R. (2019). Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. Circulation, 140(25), 2108–2118. https://doi.org/10.1161/CIRCULATIONAHA.119.042155

Chicago

Butler, Javed, Milton Packer, Stephen J. Greene, Mona Fiuzat, Stefan D. Anker, Kevin J. Anstrom, Peter E. Carson, et al. 2019. “Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.” Circulation 140 (25): 2108–18. doi:10.1161/CIRCULATIONAHA.119.042155.